Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
Conditions: T2DM (Type 2 Diabetes Mellitus); Diet, Healthy; Renal Function Disorder; Albuminuria Intervention: Drug: Sulfa-zero: possible benefits of the treatment of new generation hypoglycaemic drugs compared to sulphonylureas Sponsor: University of Milan Recruiting
CONCLUSIONS These results indicate that GDLP against T2DM-induced hepatic steatosis, oxidative stress, and inflammation by improving the Nrf2/HO-1 signaling pathway in db/db mice, suggesting the GDLP may serve as an effective strategy for in fatty liver treatment. PMID: 32245940 [PubMed - as supplied by publisher]
Publication date: Available online 4 April 2020Source: Journal of Ayurveda and Integrative MedicineAuthor(s): Naresh Kumar P, Ragavendrasamy Balakrishnan, Vibhas Kana
Publication date: Available online 5 April 2020Source: Diabetes &Metabolic Syndrome: Clinical Research &ReviewsAuthor(s): Omid Asbaghi, Faezeh Fouladvand, Sajjad Moradi, Damoon Ashtary-Larky, Razieh Choghakhori, Amir Abbasnezhad
Authors: Popa A, Georgescu M, Popa SG, Nica AE, Georgescu EF Abstract Steadily, cancer is becoming the first cause of mortality, with over 9 million deaths estimated in 2018. Increasing evidence supports a direct association between obesity, type 2 diabetes mellitus (T2DM) and cancer, with a higher risk of cancer mortality especially for some of the most common malignancies, such as breast, colon, and rectal cancers. So far, several mechanisms underlying the cancer-diabetes relationship have been investigated revealing dysregulations of the insulin-insulin-like growth factor (IGF) system as the most important parad...
Conclusions: In the current study, the prevalence of depression among diabetic outpatients was higher than that of studies conducted in other settings. Depression was significantly associated with female sex, rural residency, type 2 diabetes mellitus, duration of illness> 6 years, high fear of complications, and poor social support. PMID: 32243106 [PubMed - as supplied by publisher]
CONCLUSIONS In this study, we screened 104 lncRNA therapeutic targets and several signaling pathways (Wnt, PPAR, amino acid metabolism signaling pathway, mTOR, and lipid metabolism-related pathways) of liraglutide against T2DM based on lncRNA sequencing. PMID: 32238798 [PubMed - in process]
CONCLUSIONS A prognostic model based on six variables was predictive for incident type 2 diabetes mellitus and prediabetes in a healthy population in Japan. PMID: 32235819 [PubMed - in process]
This article is protected by copyright. All rights reserved
AbstractBackgroundRandomized controlled clinical trials (RCT) have demonstrated varied efficacy of glucagon-like peptide-1 receptor (GLP-1R) agonists for cardiovascular outcomes. We sought to evaluate the efficacy and safety of GLP-1R agonists among patients with Type 2 diabetes mellitus (DM) for stroke prevention.MethodsWe conducted a systematic review and meta-analysis of RCTs reporting the following outcomes among patients with Type 2 DM treated with GLP-1R agonists (vs. placebo): nonfatal or fatal strokes, all-cause or cardiovascular mortality, myocardial infarction (MI) and major adverse cardiovascular events (MACE). ...
oshima Michiaki Fukui Thrombopoietin (THPO) is a circulatory cytokine that plays an important role in platelet production. The presence of anti-THPO antibody relates to thrombocytopenia and is rarely seen in hematopoietic and autoimmune diseases. To date, there had been no reports that focused on the anti-THPO antibody in patients with type 2 diabetes mellitus (T2DM). To evaluate prevalence of the anti-THPO antibody in patients with T2DM and the relationship between anti-THPO antibody and platelet count, a cross-sectional study was performed on 82 patients with T2DM. The anti-THPO antibody was measured by ELISA using...